Volatus Aerospace Inc. (TAKOF)
OTCQX 
Summary
TAKOF Chart
Volatus Releases Fourth Quarter and Fiscal Year 2024 Financial Results
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQB:TAKOF) (Frankfurt:A3DP5Y/ABBA.F) ("Volatus" or "the Company"), a leader in aerial solutions, is pleased to announce its financial results for the twelve-month period and fourth quarter ended Dec 31, 2024 (“FY 2024” and “Q4 2024”, respectively). All dollar figures are stated in Canadian dollars, unless otherwise indicated.
Volatus Announces $2,000,000 Financing
Not for distribution to United States newswire services or for dissemination in the United States. TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB) (“Volatus” or the “Company”) is pleased to announce that it has filed an offering document in connection with a non-brokered private placement of up to 16,666,667 units of the Company (the “Units”) at a price of $0.12 per Unit (the “Issue Price”) for gross proceeds of up to $2,000,000.04 (the “LIFE Financing”).
Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annua
Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hypomethylating agent azacitidine, FLT3 and menin inhibitors in in-vivo AML models Actimab-A is the only CD33 targeted radiotherapy with Actinium-225 isotope payload in development for AML and other myeloid malignancies Actimab-A is currently being advanced in several combination studies including a Phase 2/3 trial in combination with CLAG-M in relapsed/refractory AML and in combination with Venetoclax and ASTX-727, an oral hypomethylating agent from Taiho Oncology in frontline AML under a CRADA with the NCI NEW YORK , April 28, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association for Cancer Research (AACR) Annual Meeting supporting Actimab-A's mutation agnostic antileukemic effect and backbone therapy potential in preclinical acute myeloid leukemia (AML) models. The preclinical data demonstrate that the combination of Actimab-A with standard of care AML therapies including menin and FLT3 inhibitors and the hypomethylating agent (HMA) azacitidine resulted in significant antileukemic activity in AML cells lines with FLT3, NPM1, KMT2A and TP53 mutations.
Volatus Aerospace Inc. Dividends
Volatus Aerospace Inc. Earnings
| 26 May 2025 (25 Days) Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 26 Aug 2024 Date | | - Cons. EPS | - EPS |
| 15 Aug 2024 Date | | - Cons. EPS | - EPS |
| 14 Aug 2024 Date | | - Cons. EPS | - EPS |
| 26 May 2025 (25 Days) Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 26 Aug 2024 Date | | - Cons. EPS | - EPS |
| 15 Aug 2024 Date | | - Cons. EPS | - EPS |
| 14 Aug 2024 Date | | - Cons. EPS | - EPS |
Volatus Aerospace Inc. (TAKOF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Volatus Aerospace Inc. ever had a stock split?
Volatus Aerospace Inc. Profile
| Steel Industry | Basic Materials Sector | Mr. Salih Cem Oral CEO | OTCQX Exchange | CA26210W1005 ISIN |
| TR Country | 4,532 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Iskenderun Demir ve Çelik A.Ş., established in 1968 and situated in Hatay, Turkey, stands as a prominent producer and distributor of iron and steel products within the Turkish market and abroad. The company’s offerings include a wide range of hot-rolled flat steel products, billets, coils, and various byproducts essential for different industrial applications. Furthermore, it extends its expertise by providing several essential services such as laboratory, port, maritime, customs, and security services. Operating under the parent company Eregli Demir ve Çelik Fabrikalari T.A.Ş., Iskenderun Demir ve Çelik A.Ş. not only caters to the domestic market but also exports its high-quality products globally.
Products and Services
- Hot-Rolled Flat Steel Products: Includes rolls or sheet metals, and plates employed in various industries for different applications.
- Billets: Offers diverse billets for manufacturing, including steel for patterned reinforcing bars, structural steel for angle bars and profiles, structural steel shapes for vessels, and special steels like chromium-alloys and high-carbon steel primarily for the automotive sector.
- Coils: Supplies steel coils used in a variety of manufacturing and construction projects.
- Byproducts: Produces a range of byproducts including motor and pure benzol, toluol, xylol, raw tar, ammonium sulfate, iron sulfate, and granulated blast furnace slag, catering to different industrial needs.
- Laboratory Services: Provides comprehensive laboratory services to ensure the quality and integrity of products.
- Port Services: Offers port services to facilitate the import and export activities, enhancing its supply chain efficiency.
- Maritime Services: Includes services related to maritime transport, ensuring efficient and secure shipping of goods.
- Customs Services: Provides assistance with customs clearance processes, making international trade smoother for clients.
- Security Services: Offers security services to ensure the safety and security of goods and operations at its facilities.
Contact Information
